Healthcare
Live Price
Offline$10.78
+1.79% today
1Y Change
-7.47%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sinopharm Group Co. Ltd. (SHTDY) is a Healthcare stock with a market cap of $50.25B and listed on OTC. The stock last traded around $10.78 and down 7.5% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -4.3%, EPS growth of -1.8%, a dividend yield of 4.0%. What stands out right now is revenue -4.3%, EPS -1.8%, free cash flow +30.7% with operating margin 2.8% and ROIC 4.8%. The dividend matters to the case here, with a current yield around 4.0%. Valuation is more restrained than many high-expectation growth names at P/E 7.1 and price/sales 0.1. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SHTDY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHTDY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHTDY Max Drawdown
-24.71%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SHTDY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$521.1B
-5.6% YoY
FY Net Income
$7.8B
-9.0% YoY
Free Cash Flow
$9.1B
+28.6% YoY
Revenue Growth
-4.3%
EPS Growth
-1.8%
Gross Margin
7.3%
Net Margin
1.2%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 559.5B | 584.5B | 596.6B | 552.1B | 521.1B |
| Gross Profit | 40.1B | 44.3B | 48.5B | 47.4B | 44.1B |
| Operating Income | 16.2B | 16.2B | 20.2B | 20.6B | 19.7B |
| EBITDA | 20.4B | 20.2B | 26.9B | 26.2B | 24.7B |
| Net Income | 7.0B | 7.0B | 9.1B | 8.5B | 7.8B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 61.6B | 54.3B | 63.8B | 55.2B | 43.5B |
| Total Assets | 390.6B | 392.8B | 383.4B | 364.8B | 335.4B |
| Total Liabilities | 256.4B | 266.1B | 263.1B | 254.7B | 235.8B |
| Shareholder Equity | 84.0B | 78.9B | 74.6B | 68.1B | 61.9B |
| Total Debt | 108.7B | 76.4B | 73.8B | 69.6B | 68.4B |
| Net Debt | 47.1B | 22.1B | 10.0B | 14.4B | 24.8B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
11.2B
+19.8% YoY
Capital Expenditures
2.1B
+7.5% YoY
Free Cash Flow
9.1B
+28.6% YoY
Key ratios
Gross Margin
7.3%
Operating Margin
2.8%
Net Margin
1.2%
ROE
8.6%
Debt / Equity
1.29x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.